Rifaximin Treatment in Hepatic Encephalopathy
Rifaximin Treatment in Hepatic Encephalopathy
About this item
Full title
Author / Creator
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this placebo-controlled, randomized trial of patients with a history of recurrent hepatic encephalopathy resulting from chronic liver disease, rifaximin (at a dose of 550 mg twice daily) prevented episodes of hepatic encephalopathy and hospitalizations involving hepatic encephalopathy.
In patients with a history of recurrent hepatic encephalo...
Alternative Titles
Full title
Rifaximin Treatment in Hepatic Encephalopathy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_733403394
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_733403394
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa0907893
